Irbesartan Sandoz (Irbesartan)

Irbesartan is an angiotensin II receptor blocker that acts on the renin‑angiotensin system to control blood pressure and related complications.

• Hypertension: reduces systolic and diastolic blood pressure in adults with high blood pressure.
• Diabetic nephropathy: slows the progression of renal impairment in patients with type 2 diabetes.
• Cardiovascular risk reduction: lowers the risk of stroke and myocardial events in hypertensive patients with left ventricular hypertrophy.

• Irbesartan selectively antagonizes the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction, aldosterone release, and sympathetic activation. By blocking this pathway, it promotes vasodilation, reduces sodium and water retention, and ultimately lowers systemic vascular resistance and arterial pressure.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or lacking energy.
• Nasal congestion: blocked or runny nose.
• Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Hyperkalemia: elevated blood potassium that can affect heart rhythm.
• Acute kidney injury: sudden decline in renal function.
• Angioedema: swelling of the face, lips, tongue, or throat.
• Liver enzyme elevation: increased ALT/AST indicating hepatic stress.
• Severe hypotension: markedly low blood pressure causing fainting.

Patients should be aware of specific safety considerations before starting therapy.

• Renal function monitoring: assess serum creatinine and eGFR regularly.
• Electrolyte checks: monitor potassium levels, especially if combined with potassium‑sparing agents.
• Pregnancy warning: contraindicated in pregnancy (Category D) due to fetal toxicity.
• Concomitant NSAIDs: avoid or use with caution as they may impair renal function.
• Volume depletion: ensure adequate hydration before initiating treatment.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Irbesartan may interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Aliskiren: combined use in diabetic patients can increase renal risk.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia.
• ACE inhibitors: concurrent use raises risk of hypotension and renal impairment.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive effect and affect kidneys.
• Lithium: may increase lithium levels, necessitating serum monitoring.
• CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma concentrations.